Skip to main content

Moderna Therapeutics and Novamax Begin Human Trials for COVID-19

Moderna Therapeutics and Novamax Begin Human Trials for COVID-1. Development progress of coronavirus therapy in Wuhan

Let us understand the situation throughly from beginning to end. Patients with new coronavirus infections that originated in Wuhan, China in December 2019 have been discovered and confirmed in many countries and regions. The geographic extent of the virus's spread and its recently discovered ability to spread through human-to-human contact have caused health officials to worry about the possibility of global spread.

As health officials scramble to learn more about the virus and its origins, researchers are working hard to develop vaccines or therapies that can help curb the global spread of the virus. Experts believe that this is technically feasible, but it also faces challenges.

Dr. Ralph Baric, who studies coronavirus at the School of Global Public Health at the University of North Carolina at Gillins University, said that the Wuhan virus (officially named 2019-nCoV) belongs to the coronavirus family. This category includes SARS (Severe Acute) Respiratory Syndrome, Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome, Middle East Respiratory Syndrome).

Although the new coronavirus is not exactly the same as SARS, their similarity allows scientists to use previous research experience and results to accelerate the development of vaccines and drugs against Wuhan coronavirus.

Dr. Anthony Fauci, long-time director of the National Institute of Allergy and Infectious Diseases (NIAID), said that after the SARS outbreak in 2003, researchers produced a vaccine and pushed it forward.

The first phase of human trials to test the safety of new drugs, but this effort has never made further progress, mainly due to the shift of research focus of participating units as the epidemic ended.

Dr. Fauci said that, theoretically, Chinese researchers have sequenced the Wuhan coronavirus. It should be fairly easy to adjust the SARS vaccine model for the unique aspects of Wuhan coronavirus.

Another option is to modify existing monoclonal antibodies that help the immune system attack foreign bodies such as viruses.

"You don't want to be too optimistic, you will indeed encounter obstacles, but fundamentally and conceptually, it is not difficult to achieve this."

Dr. Fauci added that NIAID is working with Moderna, a biotechnology company in Massachusetts, to put an experimental vaccine into a clinical trial.

He estimates that this process will take about three months and cost millions of dollars.

This does not mean that people can actually be vaccinated very quickly, because the first phase of the trial is only the first step towards safe human use, usually after animal studies and before human studies of drug efficacy.

Trials begin for Drug Development for Coronavirus by Moderna and Novamax

Whether these projects will proceed further depends largely on the results of the first phase of the trial, the duration and severity of the outbreak. But Dr. Fauci believes that the investment and efforts in this area are totally worthwhile.

Dr. Timothy Sheahan, who studies coronaviruses with Dr. Baric at the University of North Carolina, said that the development of vaccines may last longer than the disease. But this does not mean that the development of the remedy is not worth it.

The Ebola virus is a good example. In 2014, when the Ebola outbreak occurred in West Africa, it was too late when the drugs or vaccines were developed. However, when Ebola virus appeared again in Congo in 2018, the drug / vaccine has been developed. This time, the crisis was promptly responded to and the public health was improved.

 

Biotech company Moderna is developing vaccines for Wuhan coronavirus

On January 21, 2020, Moderna, a US biotechnology company founded in 2010, said in a stock exchange report that the company is working with the US government health agency to develop a vaccine for the current Wuhan coronavirus.

Specifically, the company is collaborating with the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID), and the Vaccine Research Center (VRC) to develop potential vaccines.

Moderna CEO Stephane Bancel revealed that they had produced a cancer vaccine within 40 days.

Tthey are now using the same technology for rapid development. In a document submitted to the US Securities and Exchange Commission, the company stated:

"As a fast and flexible platform, Moderna's mRNA vaccine technology is expected to be useful against emerging virus threats such as new coronaviruses.

Although we have not tested this before Rapid response capability, but Moderna confirms that it is working with NIH / NIAID / VRC to study potential vaccines for current public health emergencies. "


Development progress of coronavirus therapy in Wuhan

According to Amazon Web Services, Moderna is currently using Amazon's cloud platform to study more than a dozen drug candidates, seven of which are in human trials.

Cloud services are used to help accelerate the process from research to clinical trials.

Development progress of coronavirus therapy in Wuhan. Moderna, Novavax of the United States fully develop Wuhan coronavirus vaccine.

(Source: Moderna's official website)


The company stated that they have extensive history and extensive experience in coronavirus research including MERS and SARS and in the development of candidate vaccines.

The company said in a statement: "The company hopes to use Novavax's recombinant nanoparticle vaccine technology to develop a candidate vaccine based on the gene sequence of Wuhan coronavirus."

Novavax also plans to make full use of its proprietary Matrix-M adjuvant technology to strive to further enhance the immune response.

 

The Age of Medicine

In December 2019, patients with new coronavirus infections who had split their heads in Wuhan, China, have been found and confirmed in many countries and regions. The geographic reach of the virus and its recently discovered ability to spread through human-to-human contact have caused health officials to worry about the possibility of global spread.

As health officials scramble to learn more about the virus and its heads, researchers are working hard to develop vaccines or therapies that can help stop the virus from spreading globally. Experts believe that this is technically feasible, but it also faces provocation.

 

Dr. Ralph Baric, who studies coronavirus at the School of Global Public Health at the University of North Carolina at Gillins University, first described that the Wuhan virus (officially named 2019-nCoV) belongs to the coronavirus family.

This category includes SARS (Severe Acute Respiratory Syndrome, severe acute respiratory syndrome) and MERS (Middle East Respiratory Syndrome, Middle East Respiratory Syndrome).

Although the new coronavirus is not completely similar to SARS, but their similarity can enable scientists to use the previous research history and results to accelerate the development of vaccines and drugs against Wuhan coronavirus.

 

Dr. Anthony Fauci, who has long served as the director of the National Institute of Allergy and Infectious Diseases (NIAID), said that after the outbreak of SARS in 2003, researchers produced a vaccine and pushed it forward.

To the first phase of human trials to test the safety of new drugs, but this effort never achieved further hope, this is mainly due to the end of the epidemic on-site units shifted the focus of research.

 

According to Dr. Fauci, in theory, Chinese researchers have sequenced the Wuhan coronavirus, and it should be fairly easy to mediate the SARS vaccine model for the unique aspects of Wuhan coronavirus.

Another option is to modify existing monoclonal antibodies that help the immune system attack foreign bodies such as viruses. "You don't want to be overly optimistic, you will indeed encounter obstacles, but fundamentally and conceptually, it is not difficult to do this."

 

Dr. Fauci added that NIAID is working with Moderna, a biotechnology company in Massachusetts, to put an experimental vaccine into a phase 1 clinical trial. He estimates that this process will take about three months and cost millions of dollars.

This does not mean that people can actually be vaccinated very quickly, because the first phase of the trial is only the first step towards safe human use, usually after animal studies and before human studies of drug efficacy.

Whether these projects are further promoted depends largely on the effectiveness of the first phase of the trial, the duration and severity of the epidemic. But Dr. Fauci believes that the investment and efforts in this area are totally worth it.

 

Dr. Timothy Sheahan, who studied coronaviruses with Dr. Baric at the University of North Carolina, showed that the development of vaccines may last longer than the disease. But this does not mean that it is not worth opening up.

The Ebola virus is a good example. In 2014, when the Ebola outbreak occurred in West Africa, it was too late when the drugs or vaccines were developed.

However, when the Ebola virus appeared again in Congo in 2018, the development of drugs / vaccines was completed. This time, the crisis was promptly addressed and public health improved.

 

Biotech company Moderna Therapeutics is developing vaccines for Wuhan coronavirus

On January 21, 2020, Moderna, a US biotechnology company founded in 2010, reflected in a stock exchange report that the company is cooperating with the U.S. authorities' sanitary gas structure to develop a vaccine for the current Wuhan coronavirus.

Specifically, the company is working with the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID), and the Vaccine Research Center (VRC) to develop potential vaccines.

 

Stephane Bancel, chief executive officer of Moderna, revealed that they had produced a cancer vaccine within 40 days; they are now using similar technologies for rapid development. In a document submitted to the US Securities and Exchange Commission, the company said:

"As a platform for rapid mobility, Moderna's mRNA vaccine technology is expected to be effective against emerging virus threats (such as the new coronavirus).


Moderna confirms that it is working with NIH / NIAID / VRC

Although we have not tested this before Rapid response capability, but Moderna confirms that it is working with NIH / NIAID / VRC to study potential vaccines for current public health emergencies. "


According to Amazon Web Services, Moderna is now using Amazon's cloud platform to study more than a dozen drug candidates, seven of which are in human trials. Cloud services are used to help accelerate the process from research to clinical trials.

 

In the book of war on January 21, 2020, Novavax (NASDAQ: NVAX) of the United States showed that the company has started to develop candidate vaccines against Wuhan coronavirus.


Novavax's recombinant nanoparticle vaccine technology Use

According to the company, they have extensive history and rich experience in coronavirus research including MERS and SARS and the development of candidate vaccines. The company said in a statement:

"The company hopes to use Novavax's recombinant nano-particle vaccine technology to develop a candidate vaccine based on the gene sequence of Wuhan coronavirus."

 

Novavax is also planning to make full use of its proprietary Matrix-M adjuvant technology to capture and further enhance the immune response.


 

Comments

Popular posts from this blog

Difference Between COVID-19 Coronavirus and Other Flu Epidemic Infections

What are the differences between COVID-19 and the flu epidemic?The epidemic caused by the new Coronavirus (2019-nCoV) is still spreading. This disease, which has just been officially named COVID-19, has caused more than 40,000 infections and more than 1,000 deaths. At the same time, on the other side of the ocean, another epidemic also attracted people's attention. The flu season in the United States is on schedule. 
According to data released by the US Centers for Disease Control and Prevention, as of February 1, 22 million to 31 million people are expected to be infected during the flu season, and the number of patients dying from influenza is between 12,000 and 30,000. 
Seeing such figures, some readers may be surprised when they think: Is the flu epidemic in the United States worse? What are the differences between COVID-19 and the flu epidemic? Is this really the case? What are the differences between COVID-19 and the flu epidemic?
The facts are being unraveled below: 1. Unknown ris…

FDA Launches New Website to Encourage COVID-19 Rehabilitation Patients to Donate Plasma

According to foreign media TechCrunch, one of the ways currently being sought to develop effective treatments for COVID-19 is to use convalescent plasma. Basically, this means using plasma from COVID-19 patients who have fully recovered, hoping to transfer the antibodies they produced during the fight against the virus to others. 

US Food and Drug Administration (FDA) creates dedicated website to seek recovery plasma donationsThe US Food and Drug Administration (FDA) has created a dedicated new website that seeks recovery plasma donations from COVID-19 rehabilitation patients and explains their potential uses.
The use of plasma during recovery is hardly a new concept. In fact, it has been used since the late 1890s and was used during the Spanish influenza pandemic in 1918, although "the results were mixed."
Modern methods can help improve the efficacy and potential of recovered plasma as a therapeutic method. There are currently some drugs under development that use plasma (ani…

Physiological and Pathological Mosquitoe Floaters

What are the differences between physiological floaters and pathological floaters?What are the differences between physiological and pathological flying mosquitoes after the birth of a child? What are the differences between physiological and pathological flying mosquitoes? Experts believe everyone can guess literally. It is true that this is an ophthalmological disease. People with flying mosquitoes will have dark shadows shaking in front of their eyes when they are looking at things, and the vision is not clear, and flying mosquitoes can beFlying Mosquitoes
Mentioned flying mosquitoes, I believe everyone can literally guess that this is an ophthalmic disease, the fact is true. Patients with flying mosquitoes will have black shadows swaying in front of their eyes when watching things, and the vision is unclear.
Flying mosquitoes can be divided into physiological and pathological types. Below I will introduce you to physiological flying mosquitoes and The difference between pathologica…